Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Rhea-AI Summary

Senti Biosciences (NASDAQ: SNTI), a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies through its proprietary Gene Circuit platform, has announced an upcoming presentation. Timothy Lu, M.D., Ph.D., the company's Co-Founder and Chief Executive Officer, will present at the LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Thursday, May 29, 2025, at 2:40 PM ET.

Live webcast on Thursday, May 29th at 2:40 PM ET

SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D. Co-Founder and Chief Executive Officer of Senti Bio, will present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Thursday, May 29, 2025 at 2:40 PM ET.

Conference Details:

Conference: LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Date/Time: Thursday, May 29^th at 2:40 PM ET
Presenter: Timothy Lu, M.D., Ph.D. Co-Founder and Chief Executive Officer
Registration Link: HERE

About Webull Financial

Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology. With low-cost trading on a wide range of assets, advanced charting tools, and real-time market data, Webull is revolutionizing the way individuals approach investing. The user-centric approach and commitment to staying at the forefront of industry trends underscore the mission to provide a seamless and rewarding experience for traders of all levels. Through the Webull Group, Webull Financial and its affiliates combine to serve tens of millions of users from over 180 countries worldwide. Securities and futures trading is offered to customers by Webull Financial LLC ("Webull Financial"), a broker-dealer registered with the Securities and Exchange Commission (SEC) and a futures commission merchant registered with the Commodity Futures Trading Commission (CFTC). Webull Financial is a member of the Financial Industry Authority (FINRA), the National Futures Association (NFA), and the Securities Investor Protection Corporation (SIPC). All investing is subject to risk, including the possible loss of principal. For more information about Webull, visit www.webull.com.

About Senti Bio

Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company’s wholly-owned pipeline is comprised of cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.

Availability of Other Information About Senti Biosciences, Inc.

For more information, please visit the Senti Bio website at www.sentibio.com or follow Senti Bio on X (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
SNTI@jtcir.com

FAQ

When is Senti Biosciences (SNTI) presenting at the Webull Corporate Connect Webinar?

Senti Biosciences will present at the Webull Corporate Connect Webinar on Thursday, May 29, 2025, at 2:40 PM ET.

Who will be presenting for Senti Biosciences (SNTI) at the Webull Corporate Connect Webinar?

Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti Biosciences, will be presenting at the webinar.

What is Senti Biosciences' (SNTI) main business focus?

Senti Biosciences is a clinical-stage biotechnology company that develops next-generation cell and gene therapies using its proprietary Gene Circuit platform.

What stock exchange is Senti Biosciences (SNTI) listed on?

Senti Biosciences is listed on the Nasdaq stock exchange under the ticker symbol SNTI.